var data={"title":"Factor VIII, human plasma-derived: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIII, human plasma-derived: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5649?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viii-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, human plasma-derived: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-viii-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIII, human plasma-derived: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135729\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hemofil M;</li>\n      <li>Koate;</li>\n      <li>Koate-DVI;</li>\n      <li>Monoclate-P</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135730\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hemofil M</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051120\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051113\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-viii-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, human plasma-derived: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Children and Adults: IV: Individualize dosage based on coagulation studies performed prior to and during treatment at regular intervals: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Hemophilia A: For every 1 international unit per kg body weight of AHF (human) administered, factor VIII level should increase by 2%; calculated dosage should be adjusted to the actual vial size </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Formula to calculate dosage required, based on desired increase in factor VIII (% of normal) (<b>Note:</b> This formula assumes that the patient's baseline AHF level is &lt;1%): Units required =  Body weight (kg) x 0.5 x desired increase in factor VIII (units/dL or % of normal) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hospitalized patients: 20-50 units/kg/dose; may be higher for special circumstances. Dose can be given every 12-24 hours and more frequently in special circumstances. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemophilia A with high titer of inhibitor antibody: 50-75 units/kg/hour has been given </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>General dosing guidelines</b> (consult individual product labeling for specific dosage recommendations): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minor hemorrhage (required peak postinfusion AHF level: 20% to 40%): 10-20 units/kg; repeat every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved; mild superficial or early hemorrhages may respond to a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderate hemorrhage (required peak postinfusion AHF level: 30% to 60%): 15-30 units/kg; repeat every 12-24 hours for &ge;3 days until pain and disability are resolved </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternatively (to achieve peak postinfusion AHF level: 50%) Initial: 25 units/kg; maintenance: 10-15 units/kg every 8-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe/life-threatening hemorrhage (required peak postinfusion AHF level: 60% to 100%): 30-50 units/kg; repeat every 8-24 hours until threat is resolved </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternatively (to achieve peak postinfusion AHF level: 80% to 100%): 40-50 units/kg; maintenance: 20-25 units/kg every 8-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minor surgery (required peak postinfusion AHF level: Range 30% to 80%): 15-40 units/kg; dose is highly dependent upon procedure and specific product recommendations; for some procedures, a single dose plus oral antifibrinolytic therapy within 1 hour is sufficient; in other procedures, may repeat dose every 12-24 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Major surgery (required peak pre- and postsurgery AHF level: 80% to 100%): 40-50 units/kg; repeat every 8-24 hours depending on state of healing </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prophylaxis: May also be given on a regular schedule to prevent bleeding </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135714\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Monoclate-P: ~250 units [DSC], ~500 units [DSC], ~1000 units, ~1500 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Koate: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea) [contains albumin human, polyethylene glycol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemofil M: ~250 units (1 ea) [contains albumin human, mouse (murine) and/or hamster protein, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemofil M: ~250 units (1 ea [DSC]) [contains mouse (murine) and/or hamster protein, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemofil M: ~500 units (1 ea) [contains albumin human, mouse (murine) and/or hamster protein, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemofil M: ~500 units (1 ea [DSC]) [contains mouse (murine) and/or hamster protein, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemofil M: ~1000 units (1 ea); ~1700 units (1 ea) [contains albumin human, mouse (murine) and/or hamster protein, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Koate-DVI: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea) [contains albumin human, polyethylene glycol, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135700\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573578\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=factor-viii-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, human plasma-derived: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051124\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Parenteral: IV administration only. Administer through a separate line, do not mix with drugs or other IV fluids. Maximum rate of administration is product dependent:  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemofil M: 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoclate-P: 2 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Koate-DVI: Total dose may be given over 5 to 10 minutes; adjust administration rate based on patient response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135726\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store under refrigeration, 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Use within 3 hours of reconstitution. Do not refrigerate after reconstitution, precipitation may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemofil M: May also be stored at room temperature not to exceed 30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Koate; Monoclate-P: May also be stored at 25&deg;C (77&deg;F) for &le;6 months. Store in original package to protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051123\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and treatment of hemorrhagic episodes in patients with hemophilia A (classical hemophilia); perioperative management of patients with hemophilia A; can provide therapeutic effects in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595784\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135749\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rare but important or life-threatening: Acute hemolytic anemia, anaphylaxis (rare), blurred vision, chest tightness, chills, drowsiness, fever, headache, hemorrhagic diathesis, hypersensitivity reaction (rare), increased factor VIII inhibitors, increased serum fibrinogen, jitteriness, lethargy, nausea, pain at injection site, stomach discomfort, tingling sensation, urticaria, vasomotor symptoms (with rapid infusion), vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135720\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to antihemophilic factor (human) or any component of the formulation; hypersensitivity to mouse proteins (Hemofil M and Monoclate-P only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135704\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) may occur; discontinue immediately if hypersensitivity symptoms occur and administer appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood types A, B, and AB: Contains trace amounts of blood groups A and B isohemagglutinins; use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB. Monitor patients for signs of intravascular hemolysis and falling hematocrit; discontinue therapy and consider administration of serologically compatible type O red blood cells if progressive hemolytic anemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Products vary by preparation method; final formulations contain human albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mouse protein: Hemofil M and Monoclate-P contain trace amounts of mouse protein; use is contraindicated in patients with hypersensitivity to mouse protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; von Willebrand factor: Some products may contain naturally occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Dosage requirements will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response. Frequency of use is determined by the severity of the disorder or bleeding pattern.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819744\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur; reported incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2 to 7 days, with peak concentrations at 1 to 3 weeks after therapy; children &lt;5 years of age are at greatest risk; higher doses of AHF may be needed if antibody is present; if antibody concentration is &gt;10 Bethesda units/mL, patients may not respond to larger doses and alternative treatment modalities may be needed; monitor patients appropriately. Allergic-type hypersensitivity reactions, including anaphylaxis, may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, dyspnea, faintness, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298757\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6217988\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12748&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135710\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135722\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051119\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Bleeding; heart rate and blood pressure (before and during IV administration); AHF levels prior to and during treatment; monitor for development of inhibitor antibodies by clinical observation (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay). In patients with blood groups A, B, or AB who receive large or frequent doses, monitor Hct, direct Coombs' test, and signs of intravascular hemolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051122\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Plasma antihemophilic factor level: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal range: 50% to 150% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Level to prevent spontaneous hemorrhage: 5% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Required peak postinfusion AHF activity in blood (as % of normal or units/dL plasma): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Early hemarthrosis, muscle bleed, or oral bleed: 20% to 40% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">More extensive hemarthrosis, muscle bleed, or hematoma: 30% to 60% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Life-threatening bleeds (such as head injury, throat bleed, severe abdominal pain): 80% to 100% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minor surgery, including tooth extraction: 60% to 80% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Major surgery: 80% to 100% (pre- and postoperative)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135703\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Protein (factor VIII) in normal plasma which is necessary for clot formation and maintenance of hemostasis; activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135719\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Does not readily cross the placenta </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Mean: 14.8 to 17.5 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051129\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">One unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121603\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Monoclate-P Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Hemofil M Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1700 unit (Price provided is per AHF Unit): $1.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Koate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Koate-DVI Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $1.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135723\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>8Y (ID);</li>\n      <li>AAFact (ID);</li>\n      <li>Fandhi (IL);</li>\n      <li>Haemoctin (GB);</li>\n      <li>Haemoctin SDH (IL);</li>\n      <li>Hemofil M (DE, FR, IT, LK, TH, TW);</li>\n      <li>Koate- DVI (AE);</li>\n      <li>Koate-DVI (AR, CL, CO, CR, DO, GT, HK, HR, ID, IL, MX, PA, PH, QA, SG, SV, TR, UY);</li>\n      <li>Monoclate P (GB, IE);</li>\n      <li>Monoclate-P (AT, DK, FR, GR, KR, SE, TW);</li>\n      <li>Octonativ-M (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liesner RJ, &ldquo;Prophylaxis in Haemophilic Children,&rdquo; <i>Blood Coagul Fibrinolysis</i>, 1997, 8(Suppl 1):S7-10. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/9351529/pubmed\" target=\"_blank\" id=\"9351529\">9351529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scharrer I, Bray GL, and Neutzling O, &ldquo;Incidence of Inhibitors in Haemophilia A Patients--A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,&rdquo; <i>Haemophilia</i>, 1999, 5(3):145-54. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/10444280/pubmed\" target=\"_blank\" id=\"10444280\">10444280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shord SS and Lindley CM, &ldquo;Coagulation Products and Their Uses,&rdquo; <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/10938981/pubmed\" target=\"_blank\" id=\"10938981\">10938981</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12748 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135729\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135730\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051120\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051113\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135714\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135700\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573578\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051124\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F135726\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051123\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11595784\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135749\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135720\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135704\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819744\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298757\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6217988\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135710\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135722\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051119\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1051122\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135703\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F135719\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051129\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121603\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135723\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12748|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viii-human-plasma-derived-drug-information\" class=\"drug drug_general\">Factor VIII, human plasma-derived: Drug information</a></li><li><a href=\"topic.htm?path=factor-viii-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">Factor VIII, human plasma-derived: Patient drug information</a></li></ul></div></div>","javascript":null}